KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Receivables (2016 - 2025)

Historic Receivables for Pacific Biosciences Of California (PACB) over the last 16 years, with Q3 2025 value amounting to $30.6 million.

  • Pacific Biosciences Of California's Receivables rose 419.63% to $30.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.6 million, marking a year-over-year increase of 419.63%. This contributed to the annual value of $27.5 million for FY2024, which is 2482.86% down from last year.
  • Latest data reveals that Pacific Biosciences Of California reported Receivables of $30.6 million as of Q3 2025, which was up 419.63% from $32.3 million recorded in Q2 2025.
  • Over the past 5 years, Pacific Biosciences Of California's Receivables peaked at $36.6 million during Q4 2023, and registered a low of $12.9 million during Q1 2021.
  • Over the past 5 years, Pacific Biosciences Of California's median Receivables value was $27.9 million (recorded in 2022), while the average stood at $27.0 million.
  • As far as peak fluctuations go, Pacific Biosciences Of California's Receivables skyrocketed by 11580.66% in 2022, and later crashed by 2482.86% in 2024.
  • Pacific Biosciences Of California's Receivables (Quarter) stood at $24.2 million in 2021, then dropped by 22.5% to $18.8 million in 2022, then soared by 94.91% to $36.6 million in 2023, then fell by 24.83% to $27.5 million in 2024, then grew by 11.23% to $30.6 million in 2025.
  • Its Receivables was $30.6 million in Q3 2025, compared to $32.3 million in Q2 2025 and $31.6 million in Q1 2025.